Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 4/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5386233 | 0.88 | KMT2A (0.46) | KMT2ANPC1RAB9AMEN1NPSR1 | |
| SCHEMBL5375193 | 0.81 | TP53 (0.43) | KMT2ANPC1RAB9AMEN1NPSR1 | |
| SCHEMBL4842601 | 0.79 | SRC (0.41) | KMT2ANPC1RAB9AMEN1NPSR1 | |
| SCHEMBL5380218 | 0.79 | NPC1 (0.47) | KMT2ANPC1RAB9AMEN1NPSR1 | |
| SCHEMBL5380215 | 0.78 | NPC1 (0.62) | KMT2ANPC1RAB9AMEN1NPSR1 | |
| SCHEMBL5380161 | 0.78 | KMT2A (0.41) | KMT2ANPC1RAB9AMEN1NPSR1 | |
| SCHEMBL4832926 | 0.77 | CNR1 (0.45) | KMT2ANPC1RAB9AMEN1NPSR1 | |
| SCHEMBL8261401 | 0.77 | CNR1 (0.45) | KMT2ANPC1RAB9AMEN1NPSR1 | |
| SCHEMBL5375812 | 0.77 | NPC1 (0.45) | KMT2ANPC1RAB9AMEN1NPSR1 | |
| SCHEMBL4833400 | 0.77 | SRC (0.39) | KMT2ANPC1RAB9AMEN1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7176210-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176210-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176210-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1594872-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004069838-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-20040157838-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157838-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | KMT2A 3816/4885NPC1 650/4885RAB9A 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.